48 results on '"Schnitzler, M"'
Search Results
2. Quantifying Prognostic Impact of Prescription Narcotics Use Before Kidney Transplantation through Linked Registry and Pharmaceutical Claims Data.
3. Differential Risks For 3-Year Adverse Outcomes After Kidney Transplant Based On Initial Immunosuppression and Incorporating Claims Data Records: A National Study.
4. Racial Variation in the Use of Antihypertensive Medications After Living Kidney Donation.
5. International Comparison of the Cost-Effectiveness of VADS as Bridge to Transplant.
6. Variation in the Incidence Biliary Complications in Liver Transplantation: Outcome and Economic Implications.
7. Incremental Cost-Effectiveness of Lung Transplant By Lung Allocation Score.
8. Costs of Pediatric Kidney Transplant.
9. 5 YEAR OUTCOMES IN A RANDOMIZED TRIAL COMPARING RABBIT ANTITHYMOCYTE GLOBULIN AND BASILIXIMAB IN KIDNEY TRANSPLANT RECIPIENTS: LINKING CLINICAL TRIAL DATA WITH REGISTRY DATA
10. THE INFLUENCE OF STATINS ON POLYOMA VIRUS
11. THYMOGLOBULIN INDUCTION IN LIVING DONOR RENAL TRANSPLANT RECIPIENTS: UPDATE OF THE TAILOR REGISTRY
12. DEVELOPMENT OF DIABETES MELLITUS AFTER RENAL TRANSPLANTATION AND TACROLIMUS DOSE ADJUSTMENT
13. HIGH DONOR ANTIBODY LEVEL AND HLA C7 PREDICT SUSTAINED BK-POLYOMA VIREMIA: RESULTS OF A RANDOMIZED PROSPECTIVE TRIAL
14. CYCLOSPORINE BASED, C2 MONITORED QUADRUPLE IMMUNOSUPPRESSIVE REGIMEN RESULTS IN CYCLOSPORINE MINIMIZATION AND COST REDUCTION IN RENAL TRANSPLANT RECIPIENTS
15. Renal graft survival with tacrolimus versus cyclosporine microemulsion - a registry analysis
16. MMF DOSE MODIFICATION FOLLOWING GASTROINTESTINAL COMPLICATIONS IN RENAL TRANSPLANTATION
17. INCIDENCE AND PREDICTORS OF MYOCARDIAL INFARCTION AFTER KIDNEY TRANSPLANTATION IN THE UNITED STATES
18. INTERNATIONAL ESTIMATES OF THE LIFE-YEARS AVAILABLE FROM POTENTIAL BUT UNPROCURED DECEASED ORGAN DONORS
19. DOSE REDUCTION OF RABBIT ATG IN ADULT RENAL TRANSPLANT RECIPIENTS-1 YEAR PILOT STUDY.
20. ECONOMIC COST OF EXPANDED CRITERIA DONORS IN CADAVERIC RENAL TRANSPLANTATION
21. ECONOMIC IMPLICATIONS OF CMV-SEROLOGY MATCHING IN KIDNEY TRANSPLANTATION
22. RELATIVE COST OF CADAVERIC VERSUS LIVING DONOR KIDNEY TRANSPLANTATION
23. AN OPEN-LABEL STUDY OF 3 DAYS OF THYMOGLOBULIN FOR INDUCTION IN ADULT RENAL TRANSPLANT RECIPIENTS
24. GANCICLOVIR HAS NO IMPACT ON HHV-7 LEUKODNAEMIA
25. THE EFFECT OF SURGICAL SITE INFECTION ON OUTCOMES IN LIVER TRANSPLANTATION
26. ECONOMICS OF THYMOGLOBULIN VERSUS ATGAM FOR INDUCTION IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION
27. COST OF HLA MISMATCHES IN CADAVERIC RENAL TRANSPLANT
28. CLINICAL AND ECONOMIC IMPACT OF ORAL GANCICLOVIR PROPHYLAXIS OF CMV-DISEASE IN RENAL TRANSPLANTATION
29. THE COST OF CMV-DISEASE IN RENAL TRANSPLANTATION
30. A RANDOMIZED, DOUBLE-BLINDED COMPARISON OF THYMOGLOBULIN VS ATGAM FOR INDUCTION IN ADULT RENAL TRANSPLANT RECIPIENTS
31. THE RELATIONSHIP BETWEEN RENAL FUNCTION AND RENAL TRANSPLANT GRAFT FAILURE INCREASES OVER TIME.
32. RELATIONSHIP BETWEEN 1-YEAR POST-TRANSPLANT ESTIMATED GLOMERULAR FILTRATION RATE AND LONG-TERM KIDNEY GRAFT SURVIVAL BY DONOR TYPE.
33. PREDICTION EQUATIONS FOR GRAFT FAILURE BASED ON 12-MONTH EGFR IN THE US KIDNEY TRANSPLANT POPULATION: A VALIDATION STUDY USING THE INTERNATIONAL PORT DATABASE.
34. APPLICATION OF A VALIDATED LONG-TERM RENAL TRANSPLANT GRAFT SURVIVAL PREDICTION MODEL TO EXPECTED BELATACEPT PHASE III TRIAL OUTCOMES.
35. PROJECTING PATIENT OUTCOMES AT 20 YEARS BASED ON GRAFT FUNCTION FROM RANDOMIZED TRIALS OF IMMUNOSUPPRESSANTS AMONG RENAL TRANSPLANT RECIPIENTS IN THE UNITED STATES.
36. A PHARMACOECONOMIC ANALYSIS OF PROPHYLACTIC VS PREEMPTIVE VALGANCICLOVIR FOR THE MANAGEMENT OF CMV IN RENAL TRANSPLANT RECIPIENTS.
37. DOSE REDUCTION OF RABBIT ATG IN ADULT RENAL TRANSPLANT RECIPIENTS1 YEAR PILOT STUDY.
38. THE COST OF CMVDISEASE IN RENAL TRANSPLANTATION
39. CLINICAL AND ECONOMIC IMPACT OF ORAL GANCICLOVIR PROPHYLAXIS OF CMVDISEASE IN RENAL TRANSPLANTATION
40. A RANDOMIZED, DOUBLEBLINDED COMPARISON OF THYMOGLOBULIN VS ATGAM FOR INDUCTION IN ADULT RENAL TRANSPLANT RECIPIENTS
41. National assessment of early biliary complications after liver transplantation: economic implications.
42. ABO-incompatible living donor transplantation: is it economically "compatible"?
43. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
44. Economic cost of expanded criteria donors in cadaveric renal transplantation: analysis of Medicare payments.
45. The economic benefit of allocation of kidneys based on cross-reactive group matching.
46. Cadaveric versus living donor kidney transplantation: a Medicare payment analysis.
47. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients.
48. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.